Airsonett signs agreement with the region of Kalmar in Sweden for treatment of severe allergic asthma with TLA via public healthcare
Airsonett announced today that the company has signed an agreement with the region of Kalmar for the treatment of patients with severe allergic asthma. The agreement is the third of its kind for Airsonett in Sweden this year, for prescription of the company’s unique treatment; Temperature controlled Laminar Airflow (TLA). The technology treats severe allergic asthma patients with particle-free air.
“We are very pleased to have signed the agreement with the region of Kalmar, as the third region this year. We are also satisfied to see that the awareness of the treatment’s good results is spreading within the Swedish healthcare community and that more patients with severe allergic asthma can receive better help to achieve a better quality of life”, says Anders Due-Boje, CEO Airsonett AB.
TLA Treatment for severe asthma is part of the national guidelines for asthma treatment since 2015, and it is today prescribed to many patients in Sweden with excellent results. The treatment takes place in the home with the Airsonett Air4, a patented medical device, and fits both children and adults.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett® Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett® Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett® Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu